Theralase Technologies stock forecast
Theralase Technologies (TTX) Stock Forecast & Price Target
TTX Analyst Ratings
There are no analyst ratings in the last 3 months.
TTX Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Andre Uddin | Research Capital | EUR 0.44 | buy | 312.76%Upside | Reiterated | 05/25/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Andre UddinResearch Capital | BuyReiteratedEUR 0.44 | 05/25/26 | 312.76%Upside |
Best Analysts Covering Theralase Technologies
Copying Andre Uddin's trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of +1.24% per trade.
Copying Andre Uddin's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -7.79% per trade.
Copying Andre Uddin's trades and holding each position for 2 Years would result in 14.29% of your transactions generating a profit, with an average return of -9.64% per trade.
TTX Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 0 | 0 | 0 | 0 |
In the current month, TTX has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TTX average Analyst price target in the past 3 months is ―.
TTX Financial Forecast
TTX Earnings Forecast
Next quarter’s earnings estimate for TTX is EUR 0.00 with a range of EUR 0.00 to EUR 0.00. The previous quarter’s EPS was EUR 0.00. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.
TTX Sales Forecast
Next quarter’s sales forecast for TTX is EUR 131.88K with a range of EUR 131.88K to EUR 131.88K. The previous quarter’s sales results were EUR 103.67K. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.
